Primary effusion lymphoma
MONDO:0018842A large B-cell lymphoma located in the body cavities, characterized by pleural, peritoneal, and pericardial fluid lymphomatous effusions and that is always associated with human herpes virus-8 (HHV-8).
Also known as: PEL, body cavity-based lymphoma, primary Effusion Lymphoma, AIDS-related lymphoma
2023 clinical trials for this condition and its sub-types, 18 tagged with Primary effusion lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Gene therapy tackles HIV and lymphoma in one shot
Disease control OngoingThis early study tests whether giving gene therapy after standard chemotherapy is safe for people with AIDS-related non-Hodgkin lymphoma. The gene therapy adds anti-HIV genes to the patient's own blood stem cells, aiming to help the body fight HIV. Only 3 participants were enroll…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug combo tame a rare, untreated lymphoma?
Disease control OngoingThis trial tests whether adding lenalidomide to a standard chemotherapy regimen (DA-EPOCH) plus rituximab can help people with primary effusion lymphoma, a rare and aggressive cancer linked to the KSHV virus. The study includes adults aged 18 and older with this disease, regardle…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Promising new cocktail targets AIDS-Linked cancers
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug ibrutinib to standard chemotherapy can safely treat HIV-positive patients with a type of lymphoma. The study involves 46 participants and aims to find the best dose and check for side effects. If it works, this co…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Immunotherapy duo takes on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Gene therapy trial aims to boost HIV fight in lymphoma patients
Disease control OngoingThis early-stage study tests whether giving gene therapy after chemotherapy is safe for people with AIDS-related non-Hodgkin lymphoma. The gene therapy adds special anti-HIV genes to the patient's own blood stem cells to help the body fight HIV. Ten participants will receive the …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Hidden bone loss: HIV and cancer patients under the scanner
Knowledge-focused OngoingThis study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC